Genetic deficiency in Pparg does not alter development of experimental prostate cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12960963.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of the nuclear peroxisome proliferator-activated receptor (PPAR)-gamma in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly tested this notion using a mouse model of prostate cancer. Neither hemizygous deletion of Pparg nor complete ablation of Ppara influenced the development of prostate cancer in our experimental context.
Medical subject headings
- Neoplasms, Experimental
- Prostatic Neoplasms
- Receptors, Cytoplasmic and Nuclear
- Transcription Factors